IMS 2022 | Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies
Salomon Manier
• 27 Aug 2022
In this video, Salomon Manier, MD, PhD, Lille University, Lille, France, shares some insights into treatment strategies for late-stage multiple myeloma. Dr Manier first comments on the poor outcome associated with these patients, and then discusses the promise of anti-BCMA therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
